SWP
REGN icon

Sagespring Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Sagespring Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$782K Sell
1,012
-58
-5% -$44.4K 0.01% 387
2025
Q4 		$826K Buy
1,070
+88
+9% +$59.8K 0.02% 341
2025
Q3 		$552K Buy
982
+329
+50% +$186K 0.01% 441
2025
Q2 		$343K Sell
653
-175
-21% -$97.7K 0.01% 539
2025
Q1 		$525K Buy
828
+292
+54% +$201K 0.01% 376
2024
Q4 		$382K Buy
+536
New +$450K 0.01% 408

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Sagespring Wealth Partners's REGN Position: Q1 2026 in Review

Sagespring Wealth Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 5.4% in Q1 2026, selling an estimated $44.4K and leaving 1,012 shares worth $782K. The position accounts for 0.01% of the portfolio, ranked #387.

Sagespring Wealth Partners first reported a position in REGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $826K in Q4 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Sagespring Wealth Partners held 1,012 shares of Regeneron Pharmaceuticals worth $782K as of Q1 2026.
  • Sagespring Wealth Partners sold 58 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $44.4K.
  • Regeneron Pharmaceuticals made up 0.01% of Sagespring Wealth Partners's portfolio in Q1 2026, its #387 holding.
  • Sagespring Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Sagespring Wealth Partners's Regeneron Pharmaceuticals position peaked at $826K in Q4 2025.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Sagespring Wealth Partners's 13F filing for Q1 2026, filed 7 May 2026.